Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Jerusalem, March 16, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18 – 19, 2026. Event: Sidoti Virtual Small Cap Conference Format: Company […]
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
– Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain – – Ramping U.S. manufacturing for commercial readiness – Jerusalem, January 29, 2026 – Alpha Tau Medical […]
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
– Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients – – Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammatory effect – – Alpha DaRT currently being studied together with first-line chemotherapy in […]
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
– Initial module submission marks an important milestone in the pre-market approval process – – Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted – – Module submitted in parallel to execution of ReSTART pivotal study (Recurrent SCC Treatment […]
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
– The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones – JERUSALEM, December 18th, 2025 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer […]
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
– First patient in the world treated with Alpha DaRT® in the brain – – According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months – – This pilot study is a key part of Alpha Tau’s broader […]
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
– Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 JERUSALEM, December 4, 2025 — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that two abstracts have been accepted […]
Interview with Dr. Mark D’Andrea – Understanding Pancreatic Cancer
Understanding Pancreatic Cancer Receiving a diagnosis of pancreatic cancer can be devastating, and all too often it arrives at a stage where surgical removal is no longer an option. This is because pancreatic cancer is frequently silent until it progresses; by the time symptoms appear, the disease has often spread beyond the pancreas. Yet, despite […]
Interview with Dr. Harold Jacob on Alpha DaRT for Pancreatic Cancer
Dr. Harold Jacob Director of Advanced Gastrointestinal Endoscopy Hadassah University Medical Center Alpha TAU Medical VP Marketing Gideon Matthews, PhD recently sat with Dr. Harold Jacob, Director of Gastrointestinal Endoscopy, Hadassah University Medical Center, to discuss currently ongoing clinical trials of the Alpha DaRT® for the treatment of pancreatic cancer at Hadassah. You have many […]
Alpha DaRT Investigator Meeting in Las Vegas
Coming Up Soon – Alpha DaRT Investigator Meeting in Las Vegas Alpha Tau is pleased to announce that the Alpha DaRT Investigator Meeting, for investigators participating in the US Multicenter Pivotal Study for Skin Cancer, will be held in Las Vegas Nevada, February 27-28. We look forward to seeing our clinical collaborators at The Venetian […]